Latest Insider Transactions at Alignment Healthcare, Inc. (ALHC)
This section provides a real-time view of insider transactions for Alignment Healthcare, Inc. (ALHC). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Alignment Healthcare, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Alignment Healthcare, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 22
2022
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
100
-0.01%
|
$1,200
$12.0 P/Share
|
|
Jun 21
2022
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
3,517
-0.49%
|
$42,204
$12.01 P/Share
|
|
Jun 21
2022
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
3,583
-0.3%
|
$42,996
$12.01 P/Share
|
|
Jun 17
2022
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
12,000
-1.64%
|
$132,000
$11.18 P/Share
|
|
Jun 16
2022
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.84%
|
$110,000
$11.04 P/Share
|
|
Jun 16
2022
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
2,150
-0.13%
|
$21,500
$10.96 P/Share
|
|
Jun 02
2022
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
13,782
-0.82%
|
$151,602
$11.1 P/Share
|
|
Apr 26
2022
|
Dawn Christine Maroney President, Markets |
SELL
Bona fide gift
|
Direct |
9,415
-0.55%
|
-
|
|
Apr 25
2022
|
Dawn Christine Maroney President, Markets |
SELL
Bona fide gift
|
Direct |
1,000
-0.06%
|
-
|
|
Apr 22
2022
|
Dawn Christine Maroney President, Markets |
SELL
Bona fide gift
|
Direct |
1,000
-0.06%
|
-
|
|
Apr 12
2022
|
Dawn Christine Maroney President, Markets |
SELL
Bona fide gift
|
Direct |
15,000
-0.88%
|
-
|
|
Apr 01
2022
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,292
-0.79%
|
$36,212
$11.42 P/Share
|
|
Mar 31
2022
|
Richard A. Cross SVP, General Counsel |
SELL
Open market or private sale
|
Direct |
1,592
-0.53%
|
$17,512
$11.18 P/Share
|
|
Mar 31
2022
|
Donald Steven Furman Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
3,006
-0.16%
|
$33,066
$11.18 P/Share
|
|
Mar 31
2022
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
26,366
-3.26%
|
$290,026
$11.18 P/Share
|
|
Mar 31
2022
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
3,058
-0.26%
|
$33,638
$11.18 P/Share
|
|
Mar 31
2022
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
4,944
-1.18%
|
$54,384
$11.18 P/Share
|
|
Mar 31
2022
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
6,681
-0.39%
|
$73,491
$11.18 P/Share
|
|
Mar 31
2022
|
Rajesh Shrestha Pres., New Markets & CBO |
SELL
Open market or private sale
|
Direct |
14,224
-7.71%
|
$156,464
$11.18 P/Share
|
|
Mar 08
2022
|
Jody L Bilney Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+26.8%
|
-
|
|
Mar 08
2022
|
Thomas J. Carella Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,075
+28.49%
|
-
|
|
Mar 08
2022
|
David C Hodgson Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+25.11%
|
-
|
|
Mar 08
2022
|
Yon Jorden Director |
BUY
Grant, award, or other acquisition
|
Direct |
22,075
+30.31%
|
-
|
|
Mar 08
2022
|
Joseph S Konowiecki Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,113
+3.69%
|
-
|
|
Mar 08
2022
|
Jeffrey H Margolis Director |
BUY
Grant, award, or other acquisition
|
Direct |
19,316
+26.84%
|
-
|
|
Mar 08
2022
|
Margaret M Mc Carthy Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+21.66%
|
-
|
|
Mar 08
2022
|
Mark B. Mc Clellan Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+5.34%
|
-
|
|
Mar 08
2022
|
Nicholas Robbert Vorhoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+25.11%
|
-
|
|
Mar 08
2022
|
John E Kao Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
496,689
+38.08%
|
-
|
|
Mar 08
2022
|
Dawn Christine Maroney President, Markets |
BUY
Grant, award, or other acquisition
|
Direct |
206,954
+10.74%
|
-
|
|
Mar 08
2022
|
Robert Thomas Freeman Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
136,589
+24.52%
|
-
|
|
Mar 08
2022
|
Dinesh M. Kumar Chief Med & Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
206,954
+14.77%
|
-
|
|
Mar 08
2022
|
Richard A. Cross SVP, General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
49,669
+14.22%
|
-
|
|
Mar 08
2022
|
Jacqueline B Kosecoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
16,556
+7.32%
|
-
|
|
Jan 03
2022
|
Jody L Bilney Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,674
+50.0%
|
-
|
|
Jan 03
2022
|
Yon Jorden Director |
BUY
Grant, award, or other acquisition
|
Direct |
28,674
+50.0%
|
-
|
|
Nov 23
2021
|
Robert Thomas Freeman Chief Financial Officer |
SELL
Open market or private sale
|
Indirect |
85,279
-10.44%
|
$1,705,580
$20.11 P/Share
|
|
Nov 23
2021
|
Donald Steven Furman Chief Clinical Officer |
SELL
Open market or private sale
|
Direct |
100,000
-5.18%
|
$2,000,000
$20.11 P/Share
|
|
Nov 23
2021
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
419,646
-10.53%
|
$8,392,920
$20.11 P/Share
|
|
Nov 23
2021
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
83,367
-7.79%
|
$1,667,340
$20.11 P/Share
|
|
Nov 23
2021
|
Dawn Christine Maroney President, Markets |
SELL
Open market or private sale
|
Direct |
127,843
-7.79%
|
$2,556,860
$20.11 P/Share
|
|
Nov 23
2021
|
Mark B. Mc Clellan Director |
SELL
Open market or private sale
|
Direct |
7,500
-2.64%
|
$150,000
$20.11 P/Share
|
|
Nov 23
2021
|
Warburg Pincus Partners Gp LLC Director |
SELL
Open market or private sale
|
Indirect |
2,033,936
-8.2%
|
$40,678,720
$20.11 P/Share
|
|
Nov 23
2021
|
General Atlantic (Aln Hlth), L.P. Director |
SELL
Open market or private sale
|
Indirect |
6,259,298
-8.2%
|
$125,185,960
$20.11 P/Share
|
|
Nov 23
2021
|
General Atlantic LLC Director |
SELL
Open market or private sale
|
Indirect |
6,259,298
-8.2%
|
$125,185,960
$20.11 P/Share
|
|
Nov 23
2021
|
Warburg Pincus LLC Director |
SELL
Open market or private sale
|
Indirect |
2,033,936
-8.2%
|
$40,678,720
$20.11 P/Share
|
|
Nov 02
2021
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
29,302
-0.73%
|
$556,738
$19.93 P/Share
|
|
Nov 01
2021
|
John E Kao Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
70,698
-1.73%
|
$1,343,262
$19.91 P/Share
|
|
Nov 01
2021
|
Dinesh M. Kumar Chief Med & Operating Officer |
SELL
Open market or private sale
|
Direct |
10,000
-0.93%
|
$190,000
$19.87 P/Share
|
|
Nov 01
2021
|
Jeffrey H Margolis Director |
SELL
Open market or private sale
|
Indirect |
1,200
-0.28%
|
$22,800
$19.82 P/Share
|